<DOC>
	<DOCNO>NCT00536887</DOCNO>
	<brief_summary>Many data indicate statin increase mobilization bone marrow-derived stem cell , circulate bone marrow-derived stem cell capable home site myocardial infarction endothelial disruption , thereby restore myocardial function microvascular integrity acute myocardial infarction . Atorvastatin widely use treatment hyperlipidemia , especially acute myocardial infarction . High-dose atorvastatin know stop progression atherosclerosis decrease level inflammatory marker . The purpose prospective , randomize , single-blinded trial compare effect atorvastatin 10 mg versus 40 mg restore coronary flow reserve ( CFR ) serial bone marrow stem cell mobilization 8 month follow-up patient acute myocardial infarction .</brief_summary>
	<brief_title>Effects Atorvastatin 10 mg Versus 40 mg Eight Months Follow-up Coronary Flow Reserve Bone Marrow Stem Cell Mobilization Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description>Percutaneous coronary intervention consider gold standard primary treatment acute myocardial infarction , clinical outcome recovery myocardial contractility successful coronary intervention influence extent microvascular damage . The use intracoronary Doppler evaluation infarct-related coronary artery allow direct assessment microvascular integrity acute myocardial infarction . The assessment coronary flow reserve perform least 24 hour acute myocardial infarction , evaluate coronary flow reserve 5 day acute myocardial infarction . Intracoronary Doppler wire place distal stent , intracoronary Doppler assessment repeat 8 month coronary stenting point . 1 . Primary end point : Comparison atorvastatin 10 mg versus 40 mg 8 month follow-up coronary flow reserve ( CFR ) serial change stem cell mobilization ( CD34 , CD117 , CD133 , CXCR4+ , C-met ) acute myocardial infarction . 2 . Secondary end point : Comparison atorvastatin 10 mg versus 40 mg change level inflammatory marker ( hsCRP , IL-6 , TNF-α , adiponectin ) clinical event cardiac death , myocardial infarction , target vessel revascularization 8 month follow-up . 1 ) Study design - Prospective , randomize , single-blinded study . - Patients enrollment : 100 patient ( 50 patient group ) consider 20 % drop-out rate . - After informed consent , patient randomly assign Atorvastatin 10 mg Group Atorvastatin 40 mg Group . 2 ) Study protocol - After IRB approval , enroll within 10 month 100 acute myocardial infarction patient require stent implantation . - Study follow-up period 8 month . - Baseline clinical , laboratory , angiographic parameter obtain baseline 8 month follow-up . Out-patients follow-up schedule 4 week , 16 week , 32 week sirolimus-eluting stent implantation . - We compare atorvastatin 10 mg versus atorvastatin 40 mg change coronary flow reserve 8 month follow-up . The serial change ( baseline , 24 hour , 48 hour , 5 day , 8 month ) stem cell mobilization ( CD34 , CD117 , CD133 , CXCR4+ , C-met ) compare addition major adverse cardiac event ( cardiac death , myocardial infarction , target vessel revascularization ) inflammatory marker ( hsCRP , IL-6 , TNF-α , adiponectin ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Age 18 year Gender eligible study Patients acute myocardial infarction require sirolimuseluting stent implantation Acute myocardial infarction affect proximal mid coronary arteries No lesion great 50 percent diameter stenosis distal stent implantation Patients informed consent Left main lesion Killip Class IV acute myocardial infarction Patients current use statin Tortuous lesion difficult intracoronary Doppler wire Acute myocardial infarction affect distal coronary artery Acute myocardial infarction affect branch coronary artery The use thiazolidinediones within 3 month Previous history PCI bypass surgery infarctrelated coronary artery Patients contraindication treatment atorvastatin Pregnant lactating patient Chronic alcohol drug abuse Hepatic dysfunction ( 3 time upper normal limit 5 day AMI ) Renal dysfunction ( Creatinine great 2.0 mg/dL ) Severe Heart failure ( EF le 25 percent ) Expected life expectancy less thna 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>